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A study protocol for the N-ICE trial: A randomised double-blind placebo-
controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a
pharmacotherapy for methamphetamine ("ice") dependence
Abstract
Background: There are currently no approved pharmacotherapies for managing methamphetamine
dependence. N-acetylcysteine (NAC) has been found to reduce the craving for methamphetamine and other
drugs, but its effect on methamphetamine use and other clinically related endpoints are uncertain. The N-ICE
trial is evaluating the safety and efficacy of NAC as a take-home pharmacotherapy for methamphetamine
dependence.
Methods/design: This is a two-arm parallel double-blind placebo-controlled three-site randomised trial
(ratio 1:1) using permuted block randomisation, with variable block sizes. It is stratified by site, sex and
whether the methamphetamine is injected or not. Participants (N = 180; 60 per site) need to be dependent on
methamphetamine, interested in reducing their methamphetamine use and not currently receiving treatment
for substance use disorders. The trial is being conducted in outpatient settings in Melbourne, Geelong and
Wollongong, Australia. Participants will receive either 2400 mg oral NAC or a matched placebo, delivered as a
take-home medication for 12 weeks. Two 600 mg capsules are self-administered in the morning and two more
in the evening. Adherence is being monitored using eCAP™ medication bottle lids, which record the date and
time of each occasion the bottle is opened. The primary outcome is methamphetamine use during the
12-week trial medication period, measured as (a) days of use, assessed using the timeline followback, and (b)
methamphetamine-positive saliva tests, taken weekly. Secondary measures include weekly assessment of
methamphetamine craving, severity of methamphetamine dependence, methamphetamine withdrawal
symptoms and psychiatric symptoms (depression, suicidality, psychotic symptoms and hostility). Adverse
events are monitored at each weekly assessment. Tolerability is assessed using the Treatment Satisfaction
Questionnaire for Medication.
Discussion: The N-ICE trial is the first clinical trial to assess whether NAC can reduce methamphetamine
use. This trial will improve our understanding of the potential utility of NAC in managing methamphetamine
dependence and clinically related outcomes. If found to be effective, take-home NAC could be a potentially
scalable and affordable pharmacotherapy option for treating methamphetamine dependence.
Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12618000366257.
Registered on 29 May 2018.
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Abstract
Background: There are currently no approved pharmacotherapies for managing methamphetamine dependence.
N-acetylcysteine (NAC) has been found to reduce the craving for methamphetamine and other drugs, but its effect on
methamphetamine use and other clinically related endpoints are uncertain. The N-ICE trial is evaluating the safety and
efficacy of NAC as a take-home pharmacotherapy for methamphetamine dependence.
Methods/design: This is a two-arm parallel double-blind placebo-controlled three-site randomised trial (ratio 1:1) using
permuted block randomisation, with variable block sizes. It is stratified by site, sex and whether the methamphetamine
is injected or not. Participants (N = 180; 60 per site) need to be dependent on methamphetamine, interested in
reducing their methamphetamine use and not currently receiving treatment for substance use disorders. The trial is
being conducted in outpatient settings in Melbourne, Geelong and Wollongong, Australia. Participants will receive
either 2400mg oral NAC or a matched placebo, delivered as a take-home medication for 12 weeks. Two 600mg
capsules are self-administered in the morning and two more in the evening. Adherence is being monitored using
eCAP™ medication bottle lids, which record the date and time of each occasion the bottle is opened. The primary
outcome is methamphetamine use during the 12-week trial medication period, measured as (a) days of use, assessed
using the timeline followback, and (b) methamphetamine-positive saliva tests, taken weekly. Secondary measures
include weekly assessment of methamphetamine craving, severity of methamphetamine dependence,
methamphetamine withdrawal symptoms and psychiatric symptoms (depression, suicidality, psychotic symptoms and
hostility). Adverse events are monitored at each weekly assessment. Tolerability is assessed using the Treatment
Satisfaction Questionnaire for Medication.
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Discussion: The N-ICE trial is the first clinical trial to assess whether NAC can reduce methamphetamine use. This trial
will improve our understanding of the potential utility of NAC in managing methamphetamine dependence and
clinically related outcomes. If found to be effective, take-home NAC could be a potentially scalable and affordable
pharmacotherapy option for treating methamphetamine dependence.
Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12618000366257. Registered on 29 May
2018.
Keywords: substance use disorders, methamphetamine, N-acetylcysteine, clinical trial, craving, withdrawal, psychosis,
aggression, depression, suicide
Introduction
Methamphetamine (“ice”) use has become a global
health concern [1] and methamphetamine dependence
is now a major contributor to the burden of disease
[2]. Hence, there is an urgent need for scalable and
cost-effective treatment options [3]. However, cur-
rently there are no approved pharmacotherapies for
treating methamphetamine dependence or withdrawal
[3, 4], or its psychiatric sequelae [5, 6], with existing
treatment options entirely reliant on psychosocial in-
terventions [3]. Although these can provide a modest
benefit [7, 8], they can be resource intensive to de-
liver [9] and are typically accessed by only a minority
of consumers, particularly in rural and resource-poor
settings [10, 11]. Pharmacotherapy may be a poten-
tially scalable and cost-effective treatment option that
could dramatically increase treatment coverage.
N-acetylcysteine (NAC) is a novel non-agonist pharmaco-
therapy that targets changes in glutamate function in the
nucleus accumbens, which are thought to underpin drug
craving and drug seeking [12]. NAC has been shown to re-
duce cravings for various drugs, including cocaine, tobacco,
cannabis and methamphetamine [13]. However, evidence of
reduced substance use is mixed [14, 15] and derives mainly
from preclinical research and open-label and small-scale
trials [16–18]. One small-scale crossover trial has demon-
strated significant reductions in the craving for metham-
phetamine [19], but no trials have explored whether such
reductions in cravings translate into clinically meaningful
reductions in methamphetamine use amongst people who
are dependent on the drug.
NAC may also convey a therapeutic benefit in managing
the psychiatric sequelae associated with methamphetamine
dependence. In addition to its potential for reducing drug
cravings, pre-exposure to NAC reduces methamphetamine-
related neurotoxicity [20]. These neurotoxic changes mani-
fest as reduced dopamine and serotonin transporter density
in the frontal, striatal and limbic regions [21, 22], which cor-
relate with psychiatric symptoms, including hostility, in
chronic methamphetamine users [23, 24]. Previous clinical
trials have suggested that NAC can reduce psychiatric
symptoms in the context of bipolar disorder, schizophre-
nia and major depression [25]. However, the potential
therapeutic mitigation of psychiatric symptoms amongst
people who use methamphetamine [26, 27] has not been
explored.
NAC’s well-established safety profile means that it can
be delivered as a take-home medication [28], making it a
potentially scalable and cost-effective treatment option.
It is no longer under any patent restrictions, further en-
hancing its roll-out and take-up. Known adverse reac-
tions include gastrointestinal upsets and rash [29], which
have not been significantly elevated relative to the pla-
cebo in current NAC trials for substance use disorders
[30]. The seemingly generic effect of NAC on drug crav-
ing suggests that it may also be helpful in managing
polysubstance dependence.
Aims and hypotheses
The aim of the current trial is to test the safety and effi-
cacy of NAC as a pharmacotherapy for methamphetamine
dependence using a double-blindplacebo-controlled ran-
domised controlled trial. The trial will recruit 180 partici-
pants, who will receive either 12 weeks of oral NAC (2400
mg daily) or matched placebo. This is a phase IIb trial that
is powered to confirm whether NAC has a clinically rele-
vant benefit on methamphetamine use. The comparator
condition is a matched placebo, with all participants pro-
vided with a minimal form of intervention (a self-help
booklet), due to the lack of readily available standardised
effective treatment options for methamphetamine use.
The primary hypothesis is that daily oral NAC delivered
as a take-home medication will reduce methamphetamine
use measured as (a) days of methamphetamine use and
(b) methamphetamine-positive weekly saliva tests, during
12 weeks of active treatment relative to the placebo. The
secondary hypotheses are that daily oral NAC delivered as
a take-home medication will, relative to placebo:
– reduce the severity of methamphetamine
dependence, the craving for methamphetamine,
McKetin et al. Trials          (2019) 20:325 Page 2 of 11
methamphetamine withdrawal symptoms and
psychiatric symptoms (depressive symptoms,
suicidality, psychotic symptoms and hostility)
– have an acceptable adverse event (AE) profile
– not significantly increase the use of other substances




This is a three-site phase IIb randomised double-
blindplacebo-controlledparallel-group trial. Participants will
be recruited across three sites (N = 180; 60 per site) and ran-
domly assigned (1:1) to receive either oral NAC 2400mg
daily or the placebo, for 12weeks. Weekly assessments
throughout the 12-week medication phase will be used to
assess outcomes. The trial flow diagram is presented in
Fig. 1. The trial protocol was developed in accordance with
the Standard Protocol Items: Recommendations for Inter-
vention Trials (SPIRIT) Statement (see Additional file 1 for
the SPIRIT checklist).
Randomisation and blinding
Participants are randomised to the treatment or placebo
arms in a 1:1 ratio using a permuted block randomisa-
tion schedule with variable block sizes, stratified by site
(Melbourne, Geelong or Wollongong), gender (male or
female) and main route of methamphetamine adminis-
tration in the month prior to recruitment (injecting or
not injecting). The randomisation sequence was gener-
ated a priori using an in-house custom program written
by WL. A random seed, assigned by the data and safety
monitoring board (DSMB) statistician, was used to gen-
erate the final randomisation schedule using this pro-
gram. Allocation to treatment condition (placebo vs.
NAC) is based on the participant’s unique study identi-
fier, this being assigned by trial staff sequentially within
each stratum on randomisation.
All trial staff, the trial statistician (WL) and investiga-
tors are blind to treatment allocation. The randomisa-
tion schedule is held by the trial site pharmacy and the
DSMB statistician. Allocation to trial arm is done by the
trial pharmacist according to the randomisation sched-
ule (provided by the DSMB statistician) using the unique
study identifier provided by the trial staff. Packaging is
identical to conceal treatment allocation. A removable
adhesive label indicates whether the medication is pla-
cebo or NAC.
Unblinding is done at the discretion of the DSMB, the
trial investigators or the treating medical physician in a
medical emergency. Trial investigators can unblind indi-
vidual participants via a password-protected online portal.
Setting and study population
Participants are being recruited via outpatient settings in
Melbourne (Turning Point and Eastern Health), Geelong
(Barwon Health) and Wollongong (Illawarra Drug and Al-
cohol Service) in Australia. All participants are volunteers.
They provide written informed consent prior to participa-
tion (see Additional file 2 for the participant information
sheet and consent form). Inclusion criteria are that partici-
pants must be aged 18–60 years, meet DSM-IV criteria for
methamphetamine dependence, be seeking to reduce their
methamphetamine use but are not currently undergoing
substance use treatment (including pharmacotherapy for
substance use disorders), are not in need of acute care for
psychiatric or other medical conditions, do not have a pri-
mary psychotic disorder, are able and willing to comply with
the trial protocol, and have no contraindications for NAC.
Contraindications for receiving the trial medication include:
previous hypersensitivity to NAC; use of medications con-
taining NAC or thought to be hazardous if taken with NAC
(e.g. carbamazepine and nitroglycerin); a known or sus-
pected active systemic medical disorder including cancer or
other medical condition that may exacerbate the risk of AEs
from NAC (recent gastrointestinal ulcers or renal stones,
epilepsy or history of seizures, asthma or atopy); and, sur-
gery within the past 28 days. Further, participants must not
be pregnant (confirmed at the eligibility assessment), lactat-
ing or planning to fall pregnant during the trial.
Intervention
Randomised participants will receive 2400 mg per day of
oral NAC or a matching placebo (microcrystalline cellu-
lose), taken as two 600 mg capsules every morning and
evening for 12 weeks. The trial medication is supplied by
Pharmaceutical Packaging Professionals (PPP) Pty Ltd. It
is encapsulated in white capsules, size 00, and bottled in
identical 200 cm3 white round plastic wide-mouth
packer bottles (2.3 in. in diameter and 4.3 in. in height)
fitted with eCAP™ lids (see Adherence). As a minimal
intervention, all randomised participants are provided
with a complementary self-help booklet, On Ice (Na-
tional Drug and Alcohol Research Centre, University of
New South Wales).
Schedule of activities and study procedures
The trial flow diagram (Fig. 1) shows the schedule of
activities.
Recruitment and screening
Participants are recruited through advertisements (e.g.,
Facebook, media activity, and flyers in needle and syr-
inge programs) and word of mouth. They are screened
by phone. Potentially eligible participants are consented
by trial staff and then undergo a face-to-face eligibility
assessment (1.5 to 2 h in total) to confirm their eligibility
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and to obtain information on demographics, drug use
and psychiatric history. All participants undergo a med-
ical assessment to confirm further their eligibility prior
to randomisation. Randomisation must occur within 28
days of eligibility being confirmed. Eligible participants
are provided with a list of local health service providers
and are free to access drug treatment and other health
services during the trial. Ineligible participants are of-
fered referral to local alcohol and other drug services.
Assessments
The eligibility assessment and assessment 0 are conducted
at the trial site clinic. Weekly assessments (assessments 1–
12) are scheduled thereafter (with a leeway of −2 days to +4
days). These may be done at a public venue convenient to
the participant (e.g., a café or shopping mall) to enhance re-
tention. They take around 40min each. Detailed contact
information is collected on all participants and text mes-
sage reminders are sent prior to appointments to enhance
follow-up rates. Saliva samples are taken at each of the
follow-up assessments using a Quantisal Oral Fluid Col-
lection Device™. Participants undergo a final medical as-
sessment within 30 days of completing the trial or on
discontinuation of their medication. All participants are
provided with referral information for alcohol and other
drug treatment services at the close of the study.
Trial medication
Trial medication bottles are distributed to the trial site
pharmacy in batches. On dispensing, the adhesive label
Fig. 1 Trial flow diagram. NAC N-acetylcysteine
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indicating treatment allocation is removed by the
pharmacist and placed in the participant’s pharmacy file.
Trial medication is provided to the trial researcher who
delivers the medication to the participant at assessment
0. Medication bottles are replaced at 3-week intervals.
Participants are provided with feedback on their medica-
tion adherence at each assessment using eCAP™ technol-
ogy (Med-ic eCAP™, Information Mediary Corp, see
Adherence for details). The number of capsules remaining
in each medication bottle is audited on return.
Safety monitoring
AEs are recorded by trial research staff at each assess-
ment and reviewed by the trial physician. Face-to-face
medical assessments are scheduled for all severe and ser-
ious adverse events (SAEs), and also at the discretion of
the trial physician or at the request of the participant.
Any ongoing AEs at the end of the trial are followed for
at least 7 days, and ongoing SAEs for at least 30 days,
with all AEs followed until stabilisation or resolution. All
participants are entitled to compensation in accordance
with the Medicines Australia Compensation Guidelines.
Discontinuation of medication and withdrawal from the
trial
Participants are free to discontinue the trial medication or
withdraw from the study at any time. Investigators may
discontinue trial medication or withdraw a participant from
the trial for the following reasons: pregnancy, no longer
meeting the inclusion criteria, failing to take the medication
for 7 or more days, significant non-compliance with the
study protocol, disease progression that requires discontinu-
ation of the trial medication or a clinical condition for which
it would not be in the best interest of the participant to con-
tinue taking the trial medication. Follow-up assessments are
completed regardless of medication discontinuation for all
participants who remain consented into the study.
Endpoints and assessments
Measures and measurement time points are presented
in Table 1.
Primary endpoint
The primary outcome is methamphetamine use. There
are two measures of this endpoint:
(1) Days of methamphetamine use during the 12-week
active medication phase, assessed using the timeline
followback method (TLFB) [31] and updated
weekly. The outcome measure is the percentage of
days on which methamphetamine is used during
the 28 days prior to assessments 4, 8 and 12. The
TLFB has 88% sensitivity, 96% specificity and 0.77




0 1 2 3 4 5 6 7 8 9 10 11 12
Demographics, drug use history, CIDI (methamphetamine dependence), MINI (depression,
psychotic disorders and mania), DIP (family history of psychotic disorders), RCQ, BCIS, BIS
items, SAPAS
x
Saliva samples x x x x x x x x x x x x
TLFB for days of methamphetamine use x x x x x x x x x x x x x x
Days of other substance use x x x x x x x x x x x x x x
Adverse events x x x x x x x x x x x x
Concomitant medications x x x x x x x x x x x x x
Concomitant treatment x x x x x x x x x x x x x
SDS x x x x x x x x x x x x x
CEQ x x x x x x x x x x x x x
AWQ x x x x x x x x x x x x x
BPRS items x x x x x x x x x x x x x
WPAI-GH x x x x x x x x x x x x x
EQ-5D-5L x x x x x x x x x x x x x
Health service use and criminal justice involvement x x x x x x x x x x x x x
TSQM x x x
CIDI Composite International Diagnostic Interview, MINI Mini International Neuropsychiatric Interview, DIP Diagnostic Interview for Psychosis, RCQ Readiness to
Change Questionnaire, BCIS Beck Cognitive Insight Scale, BIS Birchwood Insight Scale, SAPAS Standardised Assessment of Personality – Abbreviated Scale, TLFB
timeline followback, SDS Severity of Dependence Scale, CEQ Craving Experience Questionnaire, AWQ Amphetamine Withdrawal Questionnaire, BPRS Brief
Psychiatric Rating Scale, WPAI-GH Work Productivity and Activity Impairment Questionnaire – General Health V2, EQ-5D-5L Five-dimension five-level version of
EuroQol questionnaire, TSQM Treatment Satisfaction Questionnaire – Medication
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test–retest agreement for the use of amphetamines
in the past 30 days [31].
(2) The number of methamphetamine-positive saliva
samples taken at assessments 1–12. Saliva is col-
lected with an Alere Quantisal Oral Fluid Collection
Device™ and the presence of methamphetamine
confirmed using mass spectrometry with a detec-
tion cut-off of >25 mg/L.
Secondary endpoints
All secondary outcomes are assessed for the past week
at assessments 0 to 12.
Methamphetamine craving Methamphetamine craving
is assessed using the total score on the Craving Experience
Questionnaire (CEQ), which has been validated for vari-
ous substances [32]. The original CEQ has ten items: three
items corresponding to the urge to use the substance,
three items corresponding to intrusive thoughts and four
items corresponding to the sensory aspects of substance
use (e.g., picture, taste, smell and feel). The sensory items
were adapted for methamphetamine and combined into
three items: (1) taste and smell combined, (2) picturing
methamphetamine and (3) imagining what it would feel
like to smoke or inject it. This gave a total of nine items,
each with scores ranging from 0 to 10 with higher scores
representing a more severe craving.
Severity of methamphetamine dependence The sever-
ity of methamphetamine dependence is assessed using
the total score on the Severity of Dependence Scale
(SDS) [33]. The SDS is a five-item scale that yields
scores from 0 (no dependence) to 15 (most severe de-
pendence). It has good internal consistency for amphet-
amine use (Cronbach’s alpha from 0.81 to 0.89) [33] and
has been validated against a diagnosis of severe amphet-
amine dependence using the Composite International
Diagnostic Interview (CIDI) [34].
Methamphetamine withdrawal symptoms Metham-
phetamine withdrawal symptoms are assessed using the
total score on the Amphetamine Withdrawal Question-
naire (AWQ) [35]. The AWQ is a ten-item question-
naire that rates various symptoms associated with
amphetamine withdrawal on a five-point Likert scale.
Scores range from 0 to 40 with higher scores indicating
higher severity. The AWQ has a test–retest reliability of
0.79 and has been validated against other measures of
withdrawal [35].
Psychiatric symptoms Psychiatric symptoms are
assessed using the Brief Psychiatric Rating Scale (BPRS)
[36]. Symptom domains are rated against anchor points
from 1 (nil) to 7 (extremely severe). Scores of 4 or greater
indicate symptoms of clinical significance or pathological
intensity. The BPRS has an inter-rater reliability of 0.83
when quality assurance procedures are followed [37]. The
following endpoint definitions were used:
 Psychotic symptoms: A score of 4 or greater on any
of the BPRS items of suspiciousness, unusual
thought content and hallucinations
 Hostility: A score of 6 or 7 on the BPRS hostility item
 Depression: A score of 4 or greater on the BPRS
depression item




The polysubstance use measure is the percentage of days
using drugs from other classes (tobacco, alcohol, cannabis,
cocaine, ecstasy, hallucinogens, inhalants and heroin) for
the 28 days prior to assessments 0, 4, 8 and 12, assessed
weekly using the TLFB, and averaged across drug types.
Adverse events
AEs will be assessed at each weekly assessment using
open-ended questions and may include any other events
that come to the attention of the trial staff during the
trial. The outcome will be the number and percentage of
participants reporting AEs and SAEs by System Organ
Classification, coded according to the Medical Diction-
ary for Regulatory Activities. AEs will be counted once
only for a given participant. The event counted will be
the event with the highest severity (coded mild, moder-
ate or severe).
Adherence
eCAP™ (Med-ic eCAP™, Information Mediary Corp) will be
used as an objective measure of medication adherence.
eCAP™ lids fitted to the medication bottles used record the
times when a bottle is opened, which are downloaded at
each assessment using a near-fieldcommunication-enabled
smartphone and on bottle return using a CertiScan RFID
desktop Reader (Med-ic Certiscan Version 2.5.1; Informa-
tion Mediary Corp 2014–2018). Adherence will be the per-
centage of compliant doses, based on bottle opening, with
dosing timeframes being morning (until 12 noon) and night
(until midnight), or equivalent 12-h intervals.
Treatment satisfaction
The Treatment Satisfaction Questionnaire for Medica-
tion (TSQM) [38] will be completed at assessments 4, 8
and 12.
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Concomitant treatments
All medications, including supplements, taken during the
trial and all treatments related to either substance use or
other mental health conditions received during the trial
will be recorded on a template adapted from the National
Institutes of Health’s concomitant medications form [39].
Health Economics
Data for costing are being collected to facilitate a subse-
quent economic evaluation of the intervention. These
costing data include the EuroQol (EQ-5D-5L) [40] ver-
sion 2.1, the Work Productivity and Activity Impairment
Questionnaire – General Health V2 (WPAI-GH), and
health service use and contact with the criminal justice
system, which are assessed using a structured question-
naire. The data are updated weekly throughout the 12-
week trial medication period.
Demographics, drug use and psychiatric history
Demographics, drug use and psychiatric history data are
collected at the eligibility assessment. Demographics and
drug use questions are based on the Opiate Treatment
Index [41] and previous drug treatment trials [42], and
include days of use for all major drug types in the past
month. Current DSM-IV methamphetamine dependence
is confirmed using CIDI [43]. The Mini International
Neuropsychiatric Interview (MINI) [44] for Schizophre-
nia and Psychotic Disorders Studies, English Version
7.0.1, is used to screen for psychotic and affective disor-
ders. Other measures include family history of psychotic
disorders, assessed using the Diagnostic Interview for
Psychosis (DIP) [45], the Readiness to Change Question-
naire (RCQ) [46], the Beck Cognitive Insight Scale
(BCIS) [47], four items from the Birchwood Insight Scale
(BIS) [48], and the Standardised Assessment of Personal-
ity – Abbreviated Scale (SAPAS) [49].
Governance and ethical considerations
Quality control
All trial researchers will receive training in the trial as-
sessment procedures. BPRS ratings are reviewed weekly,
and a selection of ratings (10%) are audio-recorded and
rated by an independent trained BPRS rater to establish
inter-rater reliability. Primary endpoints are double en-
tered. Weekly researcher meetings and monthly investi-
gator meetings are held to monitor recruitment, follow-
up, data collection and other trial procedures. A delegate
from the coordinating sponsor institution (Curtin Uni-
versity) is responsible for conducting site visits (prior to
initiation, during the trial and at trial completion) to
audit compliance with the protocol and the accuracy
and completeness of the data.
Data safety and monitoring board
The DSMB meet at least semi-annually and include
individuals with expertise in the clinical topic area
(methamphetamine and other substance use disor-
ders), randomised clinical trials and biostatistics. The
current DSMB also includes a consumer/community
representative. The role of the DSMB is to review
participant safety, recruitment, accrual, retention and
withdrawal. The DSMB can recommend trial suspen-
sion, modification or discontinuation.
Data management
Personal information obtained from participants is
stored securely and separately from trial data at the trial
site and is accessible only to trial staff from that site.
Participants’ trial data are de-identified using a unique
study identifier. Saliva samples are de-identified and
destroyed after analysis. De-identified trial data are en-
tered onto a centralised secure (password protected) on-
line electronic database, Research Electronic Data
Capture (REDCap), which is hosted on a secure Curtin
University server. De-identified trial data are available to
all trial investigators. All analyses are based on de-
identified data and will be published in a way that partic-
ipants cannot be individually identified. Trial partici-
pants will be provided with a summary of their results at
the close of the study. Otherwise, trial data are confiden-
tial and will be released in identified form only with the
permission of the participant or as required by law. Trial
data will be stored securely for 15 years after study com-
pletion; destruction of study material thereafter will be
in accordance with local ethics approvals.
Ownership and publication
The ownership and permissions relating to the trial data
are managed under a multi-institutional contractual
agreement between the study sponsors, which is avail-
able on request from RM. The decision to publish infor-
mation from the study will be made jointly by the trial
investigators. Authorship will be in accordance with the
guidelines of the International Committee of Medical
Journal Editors. There are no other restrictions on the
publication of trial results.
Governance and ethics
The N-ICE trial (Universal Trial Number U1111–1210-
1224) has been registered prospectively with the Australian
and New Zealand Clinical Trials Registry (ACTRN1261
8000366257) and has been approved by all relevant human
research ethics committees: Eastern Health (E21–2017),
Barwon Health (17/202), the University of Wollongong and
Illawarra Shoalhaven Local Health District Health (2017/
549) and Curtin University (HRE2018–0205). The trial is
funded by the National Health and Medical Research
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Council (NHMRC) under project grant 1128147 and is run
under a co-sponsor arrangement between the participating
institutions and the trial sites. The participating institutions
are Curtin University, Deakin University, the University of
Wollongong, Monash University, the Burnet Institute, La
Trobe University and the University of Newcastle. Curtin
University is the lead coordinating institution (National
Drug Research Institute, Curtin University, GPO Box 1987,
Perth WA 6845; phone +61 89,266 1602, facsimile +61 89,
266 1611). The trial sites are in Melbourne (Turning Point
and Eastern Health), Geelong (Barwon Health) and Wol-
longong (Illawarra Drug and Alcohol Service). Oversight is
provided by an independent DSMB, which operates under
a charter agreed by the DSMB members (available on re-
quest from RM). Curtin University coordinates the overall
conduct of the trial, including communication with the
DSMB, and monitors the study at all sites to ensure com-
pliance with the protocol. Each site is individually re-
sponsible for ensuring compliance with good clinical
practice and site-specific ethics protocols, including
communicating any changes of the trial protocol to
local governance authorities and participants.
Statistical considerations
Sample size estimation
The sample size of 90 participants per treatment arm is
designed to detect a mean between-group difference of
3.5 days versus 6.0 days of methamphetamine use per
month during the 12-week trial medication period with
at least 80% power at p < 0.025 (0.05 / 2 to accommodate
two primary outcome measures) and with 20% attrition
(i.e., a final sample of at least 72 participants per treat-
ment arm). The expected effect size is based on data
from the Methamphetamine Treatment Evaluation Study
(MATES) [42]. Participants who did not receive treat-
ment in that cohort showed a reduction in metham-
phetamine use from a mean (standard deviation) of 12.8
(7.4) days per month at baseline to 6.0 (6.7) days per
month at the 12-weekfollow-up. Our estimate of a min-
imal clinically meaningful reduction in use is based on
outcomes for outpatient counselling derived from
MATES: 11.2 (8.8) days per month to 3.5 (6.9) days per
month at 12 weeks. Our estimate of 20% attrition is
based on our previous research [42, 50, 51]. No interim
analyses are planned. Statistical power was estimated
using the SAMPSI command in Stata (Version 14.2, Sta-
taCorp LLC, College Station, Texas).
Efficacy analysis
All tests will be two-sided with significance set at
p < .025 for each of the two primary endpoints and
p < .01 for each of the secondary endpoints. Significance
for all other tests will be set at p < .05. The analyses will
be conducted blind to condition.
Analysis of primary outcomes Intention-to-treat ana-
lyses will be conducted for the primary outcomes. The ef-
fect of the trial medication on days of methamphetamine
use (percentage of days used in the past 28 days) will be
tested using a baseline (assessment 0) vs. medication
phase (three repeats: assessments 4, 8 and 12) by treat-
ment condition (NAC vs. placebo). Unobserved days (e.g.,
due to hospitalisation or incarceration) will be censored.
The effect of NAC on methamphetamine-positive saliva
will be tested using a main effect for treatment condition
(NAC vs. placebo) on saliva test results (positive vs. nega-
tive) from assessments 1–12 (12 repeats).
Analysis of secondary outcomes Analysis of secondary
outcomes will be based on a modified intention-to-treat
dataset that includes only participants who completed
assessment 0 and at least one follow-up assessment (i.e.,
assessments 1–12). The effect of NAC on each second-
ary outcome will be tested using a baseline (assessment
0) vs. medication phase (assessments 1–12) by treatment
condition (NAC vs. placebo) interaction.
All effects will be tested with mixed effects models
with repeated measures for each measurement time
point. Heterogeneity in variance and treatment effect be-
tween sites will be tested for by seeing whether the
model fit is significantly improved by including a ran-
dom intercept for site and a random coefficient for the
main effect by site, respectively. If no significant hetero-
geneity is found, the more parsimonious model will be
retained. Missing data will be imputed using multiple
imputation by chained equations implemented in Stata
in the analysis of the primary outcomes only. Final de-
tails of the analysis, including methods of imputation
and covariates, will be outlined in a statistical analysis
plan prior to unblinding of the data. An additional statis-
tical plan for a health economic evaluation will be devel-
oped prior to undertaking any such analysis.
Discussion
The N-ICE trial is the first randomised controlled trial
to assess the efficacy of NAC as a pharmacotherapy for
methamphetamine dependence. It will test whether
NAC can produce a clinically meaningful reduction in
methamphetamine use. It will assess whether there are
any beneficial effects of NAC on related clinical end-
points, including psychiatric symptoms, and it will docu-
ment adherence to NAC and the safety profile of NAC
as a take-home medication in this population. Thus, the
trial will improve our understanding of the potential
utility of NAC in clinical practice to reduce metham-
phetamine use.
One clear potential benefit of NAC, if it is found to be
safe and effective, is that it can be administered as a take-
home medication, making it a potentially scalable and cost-
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effective treatment option. A significant impediment to the
benefits of NAC, or any other take-home medication,
would be poor compliance with dosing regimens. Thus, we
are using electronic monitoring (eCAP™) to record the time
and date of each occasion a bottle is opened to provide an
objective measure of adherence. Electronic monitoring
through devices such as eCAP™ is a relatively recent
technological development [52] that has not yet been
widely adopted in medication trials for illicit substance
use. This technology will provide important data on the
viability of prescribing take-home medications in illicit
substance-using populations and it will also allow us to as-
sess the implications of sub-optimal dosing on treatment
effects and safety in this population.
Novel aspects of our trial procedures are the direct
community engagement strategy to recruit participants
and the outreach methods for follow-up assessments
within the community, in so far as these are practical and
safe. We have taken this approach because most people
who are dependent on methamphetamine do not engage
with specialist drug treatment services [53], and this has
made recruitment to and retention in stimulant pharma-
cotherapy trials difficult [54]. Rather than relying on
recruiting patients from existing clinical services and re-
quiring that trial participants come to fixed sites for treat-
ment, we use well-honed fieldwork methods that have
been successfully applied in survey and cohort research
involving people who use methamphetamine [42, 50, 55].
We hope that the implementation of these outreach
methods within the clinical trial framework will increase
engagement with consumers and improve retention.
A challenge that we faced in developing this trial
protocol was the lack of standardised and readily avail-
able evidence-based treatment options for metham-
phetamine dependence. This precluded a treatment
comparison arm or the provision of treatment as usual
to trial participants. Instead, we provide all participants
with a form of minimal intervention (an information
booklet) and referral information for health services,
which they are free to access throughout the trial period.
To counter the risk of bias from concomitant treatment,
we record all concomitant medications and psychosocial
treatments for substance use and other mental health
problems. We will compare treatment arms on these ex-
posures and, where differences exist, we will adjust for
these in the main analysis.
In summary, this trial is important because it tests a novel,
affordable, available and tolerable non-agonist pharmaco-
therapy option for methamphetamine dependence, which, if
effective, has the potential to be a much-needed, cost-
effective and scalable treatment option for this population.
NAC has the potential to be prescribed by primary health-
care providers as a take-home medication and used as an
adjunct to existing drug treatments. The lack of patent
restrictions and its current availability as a prescription
medication and dietary supplement will facilitate its uptake.
Given the lack of approved medications currently available
for managing methamphetamine dependence [3–5] and the
challenges involved in translating effective psychological in-
terventions into practice settings [56], the discovery of a safe
and effective pharmacotherapy would fill an important gap
in treatment options for methamphetamine use.
Trial status
The current version of the protocol that has been ap-
proved by the relevant human research ethics commit-
tees is 3.0 (29 May 2018). The first participant was
randomised on 9 July 2018. By 9 May 2019, 77 partici-
pants had been randomised. It is anticipated that recruit-
ment (N = 180) will be completed by the end of 2019.
Additional files
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Additional file 2: Participant information sheet and consent form.
(DOCX 66 kb)
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